+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hydronephrosis Therapies Market 2019-2023 - Product Image

Global Hydronephrosis Therapies Market 2019-2023

  • ID: 4668746
  • Report
  • Region: Global
  • 116 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • MORE
About Hydronephrosis

Hydronephrosis is a condition when the inside of the kidney gets dilated or stretched and usually analgesics and drugs for kidney stones are used as therapeutics for hydronephrosis.

The analysts forecast the Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the hydronephrosis therapies market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of hydronephrosis across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, hydronephrosis therapies market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
Market drivers
  • growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis
  • For a full, detailed list, view the full report
Market challenges
  • Availability of alternate therapies
  • For a full, detailed list, view the full report
Market trend
  • Increasing awareness of kidney diseases
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2023 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the Key vendors in this market space?
  • What are the market opportunities and threats faced by the Key vendors?
  • What are the strengths and weaknesses of the Key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Antibiotic therapy - Market size and forecast 2018-2023
  • Other therapies - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
PART 15: About the Author


List of Exhibits
Exhibit 01: Global urological disorder drugs market
Exhibit 02: Segments of global urological disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Antibiotic therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antibiotic therapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapies - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapies - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: ALLERGAN - Vendor overview
Exhibit 47: ALLERGAN - Business segments
Exhibit 48: ALLERGAN - Organizational developments
Exhibit 49: ALLERGAN - Geographic focus
Exhibit 50: ALLERGAN - Segment focus
Exhibit 51: ALLERGAN - Key offerings
Exhibit 52: ALLERGAN: Key customers
Exhibit 53: F. Hoffmann-La Roche - Vendor overview
Exhibit 54: F. Hoffmann-La Roche - Business segments
Exhibit 55: F. Hoffmann-La Roche - Organizational developments
Exhibit 56: F. Hoffmann-La Roche - Key customers
Exhibit 57: F. Hoffmann-La Roche - Geographic focus
Exhibit 58: F. Hoffmann-La Roche - Segment focus
Exhibit 59: F. Hoffmann-La Roche - Key offerings
Exhibit 60: Novartis - Vendor overview
Exhibit 61: Novartis - Business segments
Exhibit 62: Novartis - Organizational developments
Exhibit 63: Novartis - Geographic focus
Exhibit 64: Novartis - Segment focus
Exhibit 65: Novartis - Key offerings
Exhibit 66: Novartis - Key customers
Exhibit 67: Pfizer - Vendor overview
Exhibit 68: Pfizer - Organizational developments
Exhibit 69: Pfizer - Geographic focus
Exhibit 70: Pfizer - Segment focus
Exhibit 71: Pfizer - Key offerings
Exhibit 72: Pfizer - Key customers
Exhibit 73: Teva Pharmaceutical Industries - Vendor overview
Exhibit 74: Teva Pharmaceutical Industries - Business segments
Exhibit 75: Teva Pharmaceutical Industries - Organizational developments
Exhibit 76: Teva Pharmaceutical Industries - Geographic focus
Exhibit 77: Teva Pharmaceutical Industries - Segment focus
Exhibit 78: Teva Pharmaceutical Industries - Key offerings
Exhibit 79: Teva Pharmaceutical Industries: Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • MORE
Global Hydronephrosis Therapies Market 2019-2023

The author of the report recognizes the following company as the key player in the global hydronephrosis therapies market: Allergan, F. Hoffmann-La Roche, Novartis, Pfizer, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the increasing awareness of kidney diseases. Kidney diseases are the major causes of hydronephrosis. However, early-stage kidney disease is typically asymptomatic and may not notice any symptoms, which, in turn, leads to low levels of awareness in people with CKD.”

According to the report, one driver influencing this market is the driven by growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis. Hydronephrosis is caused by kidney related diseases such as UTIs, CKDs, and kidney stones. According to the CDC, around 30 million people in the US are affected by CKD, which is likely to augment the growth of the global hydronephrosis treatment market. Furthermore, the increasing prevalence of ESRD, another kidney related disorder, will drive the demand for treatment of hydronephrosis across the period of forecast.

Further, the report states that one challenge affecting this market is the availability of alternate therapies. The growth of the market is impeded by the fact that despite having medications for the treatment of the underlying cause of hydronephrosis, there are several alternative procedures for the management of hydronephrosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
Adroll
adroll